Historique
Article de Périodique
Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs [Protocol] (2016)
Auteur(s) :
PLATT, L. ;
REED, J. ;
MINOZZI, S. ;
VICKERMAN, P. ;
HAGAN, H. ;
FRENCH, C. ;
JORDAN, A. ;
DEGENHARDT, L. ;
HOPE, V. ;
HUTCHINSON, S. ;
MAHER, L. ;
PALMATEER, N. ;
TAYLOR, A. ;
HICKMAN, M.
Année :
2016
Page(s) :
CD012021 ; 15 p.
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Domaine :
Drogues illicites / Illicit drugs
Thésaurus mots-clés
ECHANGE DE SERINGUES
;
TRAITEMENT DE MAINTENANCE
;
REDUCTION DES RISQUES ET DES DOMMAGES
;
EFFICACITE
;
HEPATITE
;
USAGER
;
INTERVENTION
Résumé :
This is the protocol for a review and there is no abstract. The objectives are as follows:
1. To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people who inject drugs (PWID).
2. To assess the effect of OST alone on the incidence of HCV infection among PWID.
RESEARCH QUESTIONS:
1. How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among PWID?
2. How effective is OST alone for reducing HCV incidence among PWID?
3. How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)?
4. How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)?
5. How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?
1. To assess the impact of needle/syringe programmes with and without opiate substitution therapy (OST) on the incidence of HCV infection among people who inject drugs (PWID).
2. To assess the effect of OST alone on the incidence of HCV infection among PWID.
RESEARCH QUESTIONS:
1. How effective are needle/syringe programmes (NSP) with and without the use of OST for reducing HCV incidence among PWID?
2. How effective is OST alone for reducing HCV incidence among PWID?
3. How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)?
4. How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)?
5. How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?
Affiliation :
Centre for Research on Drugs and Health Behaviour, Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, UK
Titre suivant :
- Cochrane Database of Systematic Reviews, Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs [Intervention review] / L. PLATT ; S. MINOZZI ; J. REED ; P. VICKERMAN ; H. HAGAN ; C. FRENCH ; A. JORDAN ; L. DEGENHARDT ; V. HOPE ; S. HUTCHINSON ; L. MAHER ; N. PALMATEER ; A. TAYLOR ; J. BRUNEAU ; M. HICKMAN (2017)
- voir aussi :
- Addiction, Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis / L. PLATT ; S. MINOZZI ; J. REED ; P. VICKERMAN ; H. HAGAN ; C. FRENCH ; A. JORDAN ; L. DEGENHARDT ; V. HOPE ; S. HUTCHINSON ; L. MAHER ; N. PALMATEER ; A. TAYLOR ; J. BRUNEAU ; M. HICKMAN (2018)